Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01928537
Recruitment Status : Active, not recruiting
First Posted : August 26, 2013
Last Update Posted : July 24, 2018
Sponsor:
Information provided by (Responsible Party):
Onconova Therapeutics, Inc.

Tracking Information
First Submitted Date  ICMJE August 21, 2013
First Posted Date  ICMJE August 26, 2013
Last Update Posted Date July 24, 2018
Study Start Date  ICMJE August 2013
Estimated Primary Completion Date September 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 20, 2018)
Relationship of bone marrow blast response and overall survival. [ Time Frame: Up to 2 years. ]
Bone marrow blast response is defined as bone marrow (BM) complete response, ≥ 50% BM blast decrease from pretreatment value, or stable BM response (no progression) according to the International Working Group (IWG) 2006 criteria and overall survival. Overall survival is defined as the time from first study treatment to death from any cause. All patients will be followed until death and/or progression, even if they have discontinued treatment for whatever cause. Survival time of patients lost to follow-up will be censored at the time they were last known to be alive.
Original Primary Outcome Measures  ICMJE
 (submitted: August 21, 2013)
Relationship of bone marrow blast response and overall survival. [ Time Frame: Up to 2 years. ]
Bone marrow blast response is defined as bone marrow (BM) complete response, ≥ 50% BM blast decrease from pretreatment value, or stable BM response (no progression) according to the International Working Group (IWG) 2006 criteria. Overall survival is defined as the time from first study treatment to death from any cause. All patients will be followed until death and/or progression, even if they have discontinued treatment for whatever cause. Survival time of patients lost to follow-up will be censored at the time they were last known to be alive.
Change History Complete list of historical versions of study NCT01928537 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 21, 2013)
  • Number of patients with overall hematologic response. [ Time Frame: Up to 2 years after study enrollment. ]
    Overall hematologic response (complete remission [CR], partial remission [PR], bone marrow complete response [BMCR], and stable disease [SD]) is defined according to 2006 International Working Group (IWG) response criteria.
  • Number of patients with hematological improvement. [ Time Frame: Up to 2 years after study enrollment. ]
    Hematological improvement (erythroid response, platelet response and neutrophil response) is defined according to 2006 International Working Group (IWG) response criteria.
  • Number of patients with cytogenetic response. [ Time Frame: Up to 2 years after study enrollment. ]
    Cytogenetic response is defined according to 2006 International Working Group (IWG) response criteria.
  • Progression-free survival. [ Time Frame: Up to 2 years after study enrollment. ]
    Progression-free survival is defined as time from date of first dose until date when progression is documented. Progression is defined according to 2006 International Working Group (IWG) response criteria.
  • Number of patients who transition to Acute Myeloid Leukemia (AML) [ Time Frame: Up to 2 years after study enrollment. ]
    Participants who progress to Acute Myeloid Leukemia (AML) during the study. AML is defined as an increase of at least 50% bone marrow blasts, and more than 20% bone marrow blasts for Refractory Anemia with Excess Blasts types 1 and 2 (RAEB-1 and RAEB-2) and Chronic Myelomonocytic Leukemia (CMML) patients and as an increase of at least 50% bone marrow blasts for Refractory Anemia with Excess Blasts in Transformation (RAEB-t) patients.
  • Quality of Life Questionnaire [ Time Frame: Up to 2 years after study enrollment. ]
    Change from baseline in responses in the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ]-C30 version 3. Questionnaire will be administered at baseline and at 4 week intervals.
  • Infections. [ Time Frame: Up to 2 years after study enrollment. ]
    Incidence of infections requiring treatment with intravenous antimicrobials and of bleeding episodes.
  • Concentration of rigosertib in plasma. [ Time Frame: Week 1 and week 3. ]
    Concentration of rigosertib in plasma will be measured by a validated High Performance Liquid Chromatography (HPLC) method.
  • Safety. [ Time Frame: Study enrollment until 30 days after patient's last dose of rigosertib up to 2 years. ]
    Counts of patients who have adverse events (AEs). Adverse events will be grouped by system organ class (SOC) and preferred term (PT) using the most recent version of the Medical Dictionary for Regulatory Activities (MedDRA), and will be summarized by worst grade according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Official Title  ICMJE Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine
Brief Summary This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Myelodysplastic Syndromes
  • Refractory Anemia With Excess Blasts
  • Chronic Myelomonocytic Leukemia
  • Cytopenia
Intervention  ICMJE Drug: rigosertib sodium
Other Names:
  • ON 01910.Na
  • SyB L-1101
Study Arms  ICMJE Experimental: rigosertib sodium
Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
Intervention: Drug: rigosertib sodium
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: April 4, 2016)
67
Original Estimated Enrollment  ICMJE
 (submitted: August 21, 2013)
90
Estimated Study Completion Date  ICMJE February 2019
Estimated Primary Completion Date September 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of MDS confirmed within 6 weeks prior to Screening according to WHO criteria or French-American-British (FAB) classification.
  • MDS classified as follows, according to WHO criteria and FAB classification:

    • RAEB-1 (5% to 9% BM blasts)
    • RAEB-2 (10% to 19% BM blasts)
    • CMML (10% to 20% BM blasts) and white blood cells (WBC) < 13,000/μL
    • RAEB-t (20% to 30% BM blasts), meeting the following criteria: WBC < 25,000/μL at study entry; or, Stable White Blood Cell (WBC) at least 4 weeks prior to Screening and not requiring intervention for WBC control with hydroxyurea, chemotherapy, or leukopheresis.
  • At least one cytopenia (Absolute Neutrophil Count (ANC) < 1800/μL or Platelet (PLT) count < 100,000/μL or hemoglobin (Hgb) < 10 g/dL).
  • Progression (according to 2006 IWG criteria) at any time after initiation of subcutaneous or intravenous azacitidine or decitabine treatment per labeling during the past 2 years, defined as follows:

    • For patients with ˂ 5% BMBL, ≥ 50% increase in BMBL to ˃ 5% BMBL
    • For patients with 5-10% BMBL, ≥ 50% increase in BMBL to ˃ 10% BMBL
    • For patients with 10-20% BMBL, ≥ 50% increase in BMBL to ˃ 20% BMBL
    • For patients with 20-30% BMBL, ≥ 50% increase in BMBL to ˃ 30% BMBL
    • Any of the following: ≥ 50% decrease from maximum remission/response levels in granulocytes or PLT; Decrease in Hgb concentration by ≥ 2 g/dL; or, Transfusion dependence, defined as administration of at least 4 RBC units in the past 8 weeks before Screening (patients must have Hgb values ˂ 9 g/dL prior to transfusion to be considered), in the absence of another explanation.
  • Has failed to respond to, relapsed following, not eligible, or opted not to participate in bone marrow transplantation.
  • Off all other treatments for MDS for at least 4 weeks, except for azacitidine or decitabine. Filgrastim (G-CSF) and erythropoietin are allowed before and during the study as clinically indicated.
  • No medical need for induction chemotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
  • Willing to adhere to the prohibitions and restrictions specified in this protocol.
  • Patient must signed an informed consent form.

Exclusion Criteria:

  • Previous participation in a clinical study of IV or oral rigosertib.
  • Anemia due to factors other than MDS (including hemolysis or gastrointestinal [GI] bleeding) unless stabilized for 1 week after RBC transfusion.
  • Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.
  • Uncontrolled intercurrent illness including.
  • Active infection not adequately responding to appropriate therapy.
  • Total bilirubin ≥ 1.5 mg/dL not related to hemolysis or Gilbert's disease.
  • ALT/AST ≥ 2.5 x upper limit of normal (ULN).
  • Serum creatinine ≥ 2.0 mg/dL.
  • Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 mEq/L).
  • Female patients who are pregnant or lactating.
  • Patients who are unwilling to follow strict contraception requirements.
  • Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (βHCG) pregnancy test at Screening.
  • Major surgery without full recovery or major surgery within 3 weeks of Baseline/Cycle 1 Day 1 visit.
  • Uncontrolled hypertension (defined as a systolic pressure ≥160 mmHg and/or a diastolic pressure ≥ 110 mmHg).
  • New onset seizures (within 3 months prior to Baseline) or poorly controlled seizures.
  • Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy.
  • Prior treatment with low-dose cytarabine during the past 2 years.
  • Investigational therapy within 4 weeks of Baseline/Day 1 visit.
  • Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Denmark,   France,   Germany,   Italy,   Spain,   Sweden,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01928537
Other Study ID Numbers  ICMJE Onconova 04-24
2013-001124-19 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Onconova Therapeutics, Inc.
Study Sponsor  ICMJE Onconova Therapeutics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Steven M. Fruchtman, MD Onconova Therapeutics, Inc.
PRS Account Onconova Therapeutics, Inc.
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP